## Dulce Papy-Garcia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9910738/publications.pdf

Version: 2024-02-01

361413 477307 2,070 30 20 29 citations g-index h-index papers 33 33 33 3234 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Protective Effects of a synthetic glycosaminoglycan mimetic (OTR4132) in a rat immunotoxic lesion model of septohippocampal cholinergic degeneration. Glycoconjugate Journal, 2022, 39, 107-130.	2.7	O
2	Elastin-like recombinamers-based hydrogel modulates post-ischemic remodeling in a non-transmural myocardial infarction in sheep. Science Translational Medicine, 2021, 13, .	12.4	56
3	Altered heparan sulfate metabolism during development triggers dopamine-dependent autistic-behaviours in models of lysosomal storage disorders. Nature Communications, 2021, 12, 3495.	12.8	20
4	Glycosaminoglycans from Alzheimer's disease hippocampus have altered capacities to bind and regulate growth factors activities and to bind tau. PLoS ONE, 2019, 14, e0209573.	2.5	42
5	A heparan sulfate-based matrix therapy reduces brain damage and enhances functional recovery following stroke. Theranostics, 2018, 8, 5814-5827.	10.0	14
6	The role of heparan sulfates in protein aggregation and their potential impact on neurodegeneration. FEBS Letters, 2018, 592, 3806-3818.	2.8	63
7	SLC10A7 mutations cause a skeletal dysplasia with amelogenesis imperfecta mediated by GAG biosynthesis defects. Nature Communications, 2018, 9, 3087.	12.8	39
8	RGTA $\hat{A}^{\otimes}$ or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients. Glycoconjugate Journal, 2017, 34, 325-338.	2.7	55
9	Heparan sulfate proteoglycans as key regulators of the mesenchymal niche of hematopoietic stem cells. Glycoconjugate Journal, 2017, 34, 377-391.	2.7	39
10	Heparan sulfates and the decrease of N-glycans promote early adipogenic differentiation rather than myogenesis of murine myogenic progenitor cells. Differentiation, 2017, 93, 15-26.	1.9	2
11	HS3ST2 expression is critical for the abnormal phosphorylation of tau in Alzheimer's disease-related tau pathology. Brain, 2015, 138, 1339-1354.	7.6	75
12	New methods based on capillary electrophoresis for in vitro evaluation of protein tau phosphorylation by glycogen synthase kinase $3 \cdot \hat{l}^2$ . Analytical and Bioanalytical Chemistry, 2015, 407, 2821-2828.	3.7	11
13	Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E3138-47.	7.1	683
14	Selfâ€evolving oxidative stress with identifiable pre―and postmitochondrial phases in PC12 cells. Journal of Neuroscience Research, 2013, 91, 273-284.	2.9	3
15	Glycosaminoglycan Mimetic Associated to Human Mesenchymal Stem Cell-Based Scaffolds Inhibit Ectopic Bone Formation, but Induce Angiogenesis In Vivo. Tissue Engineering - Part A, 2013, 19, 1641-1653.	3.1	19
16	Age-related Changes in Rat Myocardium Involve Altered Capacities of Glycosaminoglycans to Potentiate Growth Factor Functions and Heparan Sulfate-altered Sulfation. Journal of Biological Chemistry, 2012, 287, 11363-11373.	3.4	46
17	Glycosaminoglycans from aged human hippocampus have altered capacities to regulate trophic factors activities but not Al <sup>2</sup> 42 peptide toxicity. Neurobiology of Aging, 2012, 33, 1005.e11-1005.e22.	3.1	22
18	Molecular imprinting technology for specific recognition of heparan sulfate like disaccharides. Talanta, 2012, 99, 833-839.	5 <b>.</b> 5	12

#	Article	IF	CITATION
19	Variation in Chst8 gene expression level affects PrPC to PrPSc conversion efficiency in prion-infected Mov cells. Biochemical and Biophysical Research Communications, 2011, 414, 587-591.	2.1	2
20	Glycosaminoglycans, Protein Aggregation and Neurodegeneration. Current Protein and Peptide Science, 2011, 12, 258-268.	1.4	36
21	Synthesis and biological activities of a library of glycosaminoglycans mimetic oligosaccharides. Biomaterials, 2011, 32, 769-776.	11.4	38
22	Glycosaminoglycan mimetics inhibit SDF-1/CXCL12-mediated migration and invasion of human hepatoma cells. Glycobiology, 2009, 19, 1511-1524.	2.5	34
23	Glycosaminoglycan mimetics–induced mobilization of hematopoietic progenitors and stem cells into mouse peripheral blood: Structure/function insights. Experimental Hematology, 2009, 37, 1072-1083.	0.4	35
24	Structure–activity studies of heparan mimetic polyanions for anti-prion therapies. Biochemical and Biophysical Research Communications, 2007, 363, 95-100.	2.1	18
25	Heparan Sulfate Is a Cellular Receptor for Purified Infectious Prions. Journal of Biological Chemistry, 2005, 280, 17062-17067.	3.4	150
26	Nondegradative Sulfation of Polysaccharides. Synthesis and Structure Characterization of Biologically Active Heparan Sulfate Mimetics. Macromolecules, 2005, 38, 4647-4654.	4.8	74
27	Improved and simple micro assay for sulfated glycosaminoglycans quantification in biological extracts and its use in skin and muscle tissue studies. Glycobiology, 2003, 13, 647-653.	2.5	293
28	A novel generation of heparan sulfate mimetics for the treatment of prion diseases. Journal of General Virology, 2003, 84, 2595-2603.	2.9	73
29	Pharmacological studies of RGTA11, a heparan sulfate mimetic polymer, efficient on muscle regeneration. Journal of Biomedical Materials Research Part B, 2002, 62, 525-531.	3.1	57
30	Human Plasmin Enzymatic Activity Is Inhibited by Chemically Modified Dextrans. Journal of Biological Chemistry, 2000, 275, 29383-29390.	3.4	58